Autoinflammation with infantile enterocolitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Autoinflammation with infantile enterocolitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on MAS825 for Patients with Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations https://clinicaltrials.eu/trial/study-on-mas825-for-patients-with-monogenic-il-18-driven-autoinflammatory-diseases-including-nlrc4-gof-xiap-deficiency-or-cdc42-mutations/ Wed, 29 Apr 2026 14:28:37 +0000 https://clinicaltrials.eu/trial/study-on-mas825-for-patients-with-monogenic-il-18-driven-autoinflammatory-diseases-including-nlrc4-gof-xiap-deficiency-or-cdc42-mutations/ This clinical trial is focused on studying certain rare autoinflammatory diseases, which are conditions where the immune system mistakenly attacks the body, causing inflammation. The specific diseases being studied include NLRC4-Gain of Function (GOF), also known as autoinflammation with infantile enterocolitis (AIFEC), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, and CDC42 mutations. These conditions can lead to various symptoms, including fever, rash, and joint pain, due to the body’s immune response being overactive.

The treatment being tested in this study is called MAS825, which is a type of medication known as a human IgG1 monoclonal antibody. This medication works by targeting specific proteins in the body, IL-1 beta and IL-18, which are involved in the inflammatory process. By blocking these proteins, MAS825 aims to reduce inflammation and prevent disease flares, which are periods when symptoms worsen. Some participants in the study will receive MAS825, while others will receive a placebo, which is a substance with no active medication.

The purpose of the study is to evaluate how effective and safe MAS825 is in preventing flares in patients with these autoinflammatory diseases. Participants will receive the treatment through an injection into a vein, and the study will be conducted over several periods. During these periods, the health and response of the participants will be closely monitored to assess the treatment’s impact on their condition. The study aims to provide valuable information on whether MAS825 can help manage these rare diseases effectively.

]]>